Hormone Therapy Without the Fear: What WHI, KEEPS and the 2026 Data Actually Show

The short version: hormone therapy is the most effective treatment for menopause symptoms ever tested — about a 75% reduction in hot-flash frequency versus placebo — with a favorable benefit–risk profile for most women under 60 or within 10 years of their final period who don't have contraindications. It prevents bone loss. And the catastrophic reputation it carries traces to one study whose participants didn't match the women actually taking it.

How well does it work?

From The Menopause Society's 2022 position statement: compared with placebo, estrogen alone or estrogen-plus-progestogen reduced weekly symptom frequency by 75% (95% CI, 64–82%) and severity dramatically (odds ratio 0.13), with "no other pharmacologic or alternative therapy found to provide more relief." It simultaneously prevents post-menopausal bone loss and fracture, and treats genitourinary symptoms.

The WHI story: how one trial reshaped a decade of fear

In 2002, the Women's Health Initiative reported higher breast cancer, stroke, and clot rates in women taking combined hormone therapy. Headlines worldwide announced that hormones cause cancer. Prescriptions halved within two years.

What got lost:

• Average participant age was 63 — roughly 13 years past menopause onset. Hormone therapy was never indicated for that population.
• One formulation (oral conjugated equine estrogens + medroxyprogesterone) was tested, then generalized to all routes and doses.
• The younger subgroup told a different story. In WHI's 50–59 cohort followed ~18 years, all-cause mortality was lower with hormones than placebo (HR 0.69).
• The regulatory system caught up. From late 2025 through 2026, the FDA removed blanket boxed warnings from menopausal hormone therapy labeling — coverage spanned PBS, Cedars-Sinai, Health.com and others.

The timing hypothesis

Observational data has long suggested hormone therapy is cardioprotective when started near menopause and potentially harmful when started decades later. WHI's design couldn't test this directly — which is why professional guidance centers on the window: under 60, or within 10 years of onset. Within that window without contraindications, consensus holds the benefit–risk ratio favorable for bothersome symptoms.

The brain question: three honest findings

1. RCT evidence — neutral. The Kronos Early Estrogen Prevention Study (KEEPS) gave healthy recently-menopausal women 4 years of hormone therapy, then assessed brain amyloid and structure a decade later: no adverse effects and no benefit. Findings "support the long-term safety of short-term use of mHT on brain health."
2. Observational evidence — protective signal. A 2026 Neurology cohort study (Stanford/ADNI) found estrogen-only users had significantly lower odds of Alzheimer's pathology at autopsy (OR 0.65) and clinical dementia (OR 0.61). The authors explicitly note this cannot prove causation.
3. RCT-only review — no proven benefit. A 2026 JRSM Open systematic review of 17 randomized trials found hormone therapy in younger menopausal women has not been shown to improve cardiovascular disease, cancer, depression, or cognition outcomes.

Risks, in actual numbers

From WHI and subsequent meta-analyses, risks differ by regimen:

• Breast cancer: a small increase associated specifically with combined estrogen-plus-progestin therapy used over years; estrogen-alone showed reduced incidence in WHI.
• VTE (blood clots): increased with oral estrogen — observational data suggests transdermal (patch/gel) routes carry less risk.
• Stroke & gallbladder disease: rare absolute increases, age-dependent.
• If you have a uterus: estrogen must be paired with a progestogen to protect the uterine lining — this is non-negotiable physiology, not preference.

Contraindications that change the conversation entirely: prior estrogen-sensitive cancer, prior clot/stroke/heart attack, active liver disease — plus simple personal preference, which is fully legitimate given the Level-I non-hormonal alternatives.

What this means practically

1. Bothersome symptoms + under 60/within 10 years + no contraindications → hormone therapy is a reasonable first-line discussion with real numbers behind it.
2. Outside that window or with contraindications → effective non-hormonal prescriptions exist (Level I), plus hypnosis/CBT with RCT support.
3. Either way: periodic re-evaluation is guideline-standard, not a sign something went wrong.

Frequently asked questions

References